Key to success of drug-resistant bacteria

2022-04-14 - 2022-04

Researchers have uncovered how Gram-negative bacteria -- which cause a variety of drug-resistant infections -- build their protective outer layer, which could lead to more effective treatments.

Drug use severity in adolescence affects substance use disorder risk in adulthood

2022-04-14 - 2022-04

People who reported multiple symptoms consistent with severe substance use disorder at age 18 exhibited two or more of these symptoms in adulthood, according to a new analysis of a nationwide survey in the United States. These individuals were also more likely, as adults, to use and misuse prescription medications, as well as self-treat with opioids, sedatives, or tranquillizers.

Experimental ‘gene silencing’ therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98%

2022-04-14 - 2022-04

Findings from a phase 1 trial show that an experimental 'gene silencing' therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

FDA approved new immunotherapy regimen for patients with melanoma

2022-04-14 - 2022-04

The U.S. Food and Drug Administration has approved a novel therapy for patients with metastatic or inoperable melanoma, an aggressive type of skin cancer.

Brochure Form

Abstracts enquiry

Registration enquiry

Contact Enquiry

Sponsors / Advertising

Phone

WhatsApp

Useful Links

News

Key to success of drug-resistant bacteria

Drug use severity in adolescence affects substance use disorder risk in adulthood

Experimental ‘gene silencing’ therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98%

FDA approved new immunotherapy regimen for patients with melanoma

Newsletter

Brochure

Clinical Pharmacy and Pharmacology

Brochure Form

Key to success of drug-resistant bacteria

Drug use severity in adolescence affects substance use disorder risk in adulthood

Experimental ‘gene silencing’ therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98%

FDA approved new immunotherapy regimen for patients with melanoma